CT Scan, Inc. (DYNO)

Two halves of one job. DYNO is the predictive side: it reads the protocol, extracts eligibility criteria, models the addressable population, and runs a seven-stage funnel model to predict cost per lead, cost per enrollment, advertising budget, and the enrollment timeline. CT Scan, Inc. is the operational side: we then run the recruitment — the advertising, the pre-screening, and the referral flow into your sites — against that model. We do not sell software licences and there is nothing here for a sponsor to log into and operate alone.

Three components: an initiation fee, the advertising budget (spent on media, not retained by us), and a per-enrollment fee. Because we model cost per enrollment up front, the budget is sized to a specified number of patients rather than quoted as an open-ended campaign. There is no subscription and no software licence. Ask us for the modelled cost per enrollment in writing before you commit, and hold us to it.

Whatever the structure, convert it to cost per randomized patient before you compare proposals. Cost per referral is the number vendors prefer to quote and the number that tells you least.

• Priced on enrollments, not referrals — the advertising budget is derived from a modelled cost per enrollment for a stated patient number
• Prediction and delivery are the same team, so the forecast is not somebody else's problem when the campaign runs
• Protocol-level modelling of eligibility and addressable population before a dollar of media is spent

• We publish this directory, so treat our self-assessment as marketing until you have verified it
• A model is a model. Ask us for predicted versus actual cost per enrollment on past studies, the same question you should put to every vendor here
• If your protocol's eligible population is genuinely tiny, no amount of advertising modelling fixes that, and we will say so rather than sell you a budget

Worth it when: Sponsors and CROs who need a defensible number for what enrolling N patients will cost, and then want that same number delivered against operationally.

Not worth it when: Teams looking to buy a self-serve forecasting tool to run themselves, or studies where enrollment cannot be influenced by patient-facing advertising at all.

• AutoCruitmentDirect-to-patient digital recruitment with a proprietary pre-screener.
• AntidoteMatches patients through a network of health advocacy and publisher partners.
• TrialfactsGuarantee-backed recruitment aimed at smaller and investigator-initiated studies.

Ask for the referral-to-randomization ratio on three studies resembling yours, in the same indication and the same countries. If a vendor will not give it, that is the answer. If your enrollment forecast itself is the shaky part, our sister publication Rock Enroll covers forecasting and rescue in depth.